Quarterly report · Q1
9627.TEDINET S100RUX5
Period2023-05-01 → 2023-07-31
Filed2023-09-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥94.7bn | 2023-05-01 → 2023-07-31 | Cons. | Net sales |
| Revenue | ¥358.7bn | 2022-05-01 → 2023-04-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥81.5bn | 2022-05-01 → 2022-07-31 | Cons. | Net sales |
| Operating income | ¥3.6bn | 2023-05-01 → 2023-07-31 | Cons. | Operating income |
| Operating income | ¥2.8bn | 2022-05-01 → 2022-07-31 | Cons. | Operating income |
| Ordinary income | ¥3.9bn | 2023-05-01 → 2023-07-31 | Cons. | Ordinary income |
| Ordinary income | ¥17.1bn | 2022-05-01 → 2023-04-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2022-05-01 → 2022-07-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.9bn | 2023-05-01 → 2023-07-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.0bn | 2022-05-01 → 2022-07-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2023-05-01 → 2023-07-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.2bn | 2022-05-01 → 2023-04-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.7bn | 2022-05-01 → 2022-07-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2023-05-01 → 2023-07-31 | Cons. | Profit loss |
| Net income | ¥1.7bn | 2022-05-01 → 2022-07-31 | Cons. | Profit loss |
| Total assets | ¥235.6bn | at 2023-07-31 | Cons. | Assets |
| Total assets | ¥231.8bn | at 2023-04-30 | Cons. | Assets |
| Total assets | ¥228.6bn | at 2022-07-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥109.0bn | at 2023-07-31 | Cons. | Liabilities |
| Total liabilities | ¥105.2bn | at 2023-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥126.6bn | at 2023-07-31 | Cons. | Net assets |
| Net assets / equity | ¥126.5bn | at 2023-04-30 | Cons. | Net assets |
| Net assets / equity | ¥118.8bn | at 2022-07-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥47.4bn | at 2023-07-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.8bn | at 2023-04-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥60.93 | 2023-05-01 → 2023-07-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥262.87 | 2022-05-01 → 2023-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.54 | 2022-05-01 → 2022-07-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 53.7% | at 2023-07-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.6% | at 2023-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.9% | at 2022-07-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2023-05-01 → 2023-07-31 | ¥2.8bn |
| Otherother segments | revenue external | 2023-05-01 → 2023-07-31 | ¥2.8bn |
| Otherother segments | revenue intersegment | 2023-05-01 → 2023-07-31 | ¥12m |
| Otherother segments | segment ordinary income | 2023-05-01 → 2023-07-31 | −¥5m |
| Reconciling Itemsreconciling | revenue | 2023-05-01 → 2023-07-31 | −¥12m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-05-01 → 2023-07-31 | −¥12m |
| Reconciling Itemsreconciling | segment ordinary income | 2023-05-01 → 2023-07-31 | −¥2.3bn |
| jpcrp040300-q1r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2023-05-01 → 2023-07-31 | ¥84.4bn |
| jpcrp040300-q1r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2023-05-01 → 2023-07-31 | ¥84.4bn |
| jpcrp040300-q1r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2023-05-01 → 2023-07-31 | ¥5.4bn |
| jpcrp040300-q1r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2023-05-01 → 2023-07-31 | ¥7.4bn |
| jpcrp040300-q1r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2023-05-01 → 2023-07-31 | ¥7.4bn |
| jpcrp040300-q1r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2023-05-01 → 2023-07-31 | ¥710m |
| —segment total | revenue | 2023-05-01 → 2023-07-31 | ¥94.7bn |
| —segment total | revenue external | 2023-05-01 → 2023-07-31 | ¥94.7bn |
| —segment total | revenue intersegment | 2023-05-01 → 2023-07-31 | ¥12m |
| —segment total | segment ordinary income | 2023-05-01 → 2023-07-31 | ¥6.1bn |
| Otherother segments | revenue | 2022-05-01 → 2022-07-31 | ¥2.9bn |
| Otherother segments | revenue external | 2022-05-01 → 2022-07-31 | ¥2.9bn |
| Otherother segments | revenue intersegment | 2022-05-01 → 2022-07-31 | ¥18m |
| Otherother segments | segment ordinary income | 2022-05-01 → 2022-07-31 | ¥4m |
| Reconciling Itemsreconciling | revenue | 2022-05-01 → 2022-07-31 | −¥18m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-05-01 → 2022-07-31 | −¥18m |
| Reconciling Itemsreconciling | segment ordinary income | 2022-05-01 → 2022-07-31 | −¥1.8bn |
| jpcrp040300-q1r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2022-05-01 → 2022-07-31 | ¥72.5bn |
| jpcrp040300-q1r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2022-05-01 → 2022-07-31 | ¥72.5bn |
| jpcrp040300-q1r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2022-05-01 → 2022-07-31 | ¥4.7bn |
| jpcrp040300-q1r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2022-05-01 → 2022-07-31 | ¥6.1bn |
| jpcrp040300-q1r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2022-05-01 → 2022-07-31 | ¥6.1bn |
| jpcrp040300-q1r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2022-05-01 → 2022-07-31 | ¥164m |
| —segment total | revenue | 2022-05-01 → 2022-07-31 | ¥81.5bn |
| —segment total | revenue external | 2022-05-01 → 2022-07-31 | ¥81.5bn |
| —segment total | revenue intersegment | 2022-05-01 → 2022-07-31 | ¥18m |
| —segment total | segment ordinary income | 2022-05-01 → 2022-07-31 | ¥4.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 369
| Item | Context | Value | Unit |
|---|---|---|---|
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentQuarterInstant | Text · Plus | |
| Notes quarterly consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |